Inari Medical Inc. Q3 2024 Earnings Report

Inari Medical Inc. (NARI) reported a robust third quarter for 2024, achieving record revenues of $153.4 million, a 21% increase year-over-year. The company specializes in innovative medical devices for thrombectomy procedures and has raised its full-year revenue guidance, projecting operating profitability in the first half of 2025.

International sales surged, especially in Europe and Latin America, aided by regulatory approvals in Brazil, China, and Japan. Despite this quarter's GAAP operating loss, Inari Medical is optimistic due to the anticipated impact of PEERLESS trial data and growth in its Emerging Therapies segment.

Key Takeaways

• Q3 2024 Revenue: Increased by 21% YoY to $153.4 million.
• International Sales Growth: Up 76.4%, particularly in Europe and Latin America.
• Full-Year Revenue Outlook: Raised to between $601.5 million and $604.5 million.
• GAAP Losses: Q3 GAAP operating loss of $13.6 million; net loss of $18.4 million.
• Future Growth Drivers: Anticipated positive impact from the PEERLESS trial, along with innovations like LimFlow and Artix products.

Company Outlook

Inari Medical aims for sustained operating profitability by mid-2025 and anticipates that the Emerging Therapies segment could contribute at least 20% of total revenue in the future.

Challenges and Opportunities

Bearish Highlights

• Q3 Losses: Reported a GAAP operating loss and a widening net loss compared to the previous year.
• Operating Expenses: Increased to $147.1 million.

Bullish Highlights

• VTE Market Growth: Stable pricing trends, with strong adoption driven by regulatory approvals in key international markets.
• Emerging Therapies Performance: Emerging Therapies revenue grew 64%, with high hopes for LimFlow and Artix products.

Misses

• Loss per Share: Despite record revenue, the company reported a loss of $0.31 per share.
• Net Loss Comparison: Widened to $18.4 million from a profit of $2.1 million in Q3 2023.

Q&A Highlights

During the conference call:
– Discussion focused on the unique features of the FlowTriever system compared to conventional methods.
– Reports indicated a $9 million sequential improvement in operating profitability, excluding one-time impairment charges.

Inari Medical's Q3 performance reflects a transition phase, underscoring international expansion and product development while aiming for profitability. With the upcoming PEERLESS trial data and continued growth in Emerging Therapies, Inari is strategically positioned for future market dominance. However, achieving sustained profitability remains a critical focus as they navigate growth challenges.

Conclusion

Inari Medical's advancements during Q3 2024 suggest a promising trajectory as they push towards profitability while expanding into new markets and enhancing their product offerings. The company remains committed to improving specifications and generating positive clinical outcomes for patients suffering from venous thromboembolism.